Hypothesis

High mTORC1 activity locks cells into a proliferative, differentiation‑competent state by maintaining an open chromatin landscape at lineage‑specifying enhancers, whereas low mTORC1 activity triggers a rapid chromatin closing at those same sites and opens stress‑response promoters, creating a bistable switch that defines the quiescence‑senescence continuum. Rapamycin shifts the bifurcation point earlier along pseudotime, forcing cells to abandon the "civilization" program before they have completed differentiation.

Mechanistic Reasoning

1. mTORC1‑dependent histone acetylation – mTORC1 activates S6K1, which phosphorylates and activates the histone acetyltransferase p300/CBP. High mTORC1 thus sustains acetylation at enhancers of proliferation genes (e.g., Myc, E2f targets). When mTORC1 is inhibited, p300/CBP activity drops, leading to deacetylation and nucleosome compaction at those enhancers.
2. Reciprocal regulation of FOXO transcription factors – Low mTORC1 relieves FOXO phosphorylation, allowing nuclear translocation. FOXO binds to nucleosome‑remodeled regions and recruits SWI/SNF complexes that open chromatin at autophagy and oxidative‑stress genes (e.g., LC3, SOD2). This creates a positive feedback loop where FOXO activity reinforces the low‑mTOR state.
3. Bistable switch via mutual inhibition – The mTORC1‑p300 axis and FOXO‑SWI/SNF axis inhibit each other through competing chromatin states. Mathematical modeling predicts two stable attractors: a high‑acetylation/proliferation attractor and a low‑acetylation/stress‑resistance attractor, separated by an unstable threshold.
4. Pseudotime trajectory prediction – In aging tissues, cells gradually increase stress signals, moving along a pseudotime axis toward the unstable threshold. The point where mTORC1 activity falls below the threshold corresponds to a sharp transcriptional shift: downregulation of cell‑cycle genes and upregulation of SASP‑suppressing, autophagy‑related genes.

Testable Predictions

• Prediction 1: Single‑cell multi‑omics (scRNA‑seq + scATAC‑seq + phospho‑S6 staining) from aged mouse liver will reveal a distinct inflection point in pseudotime where phospho‑S6 signal drops sharply, coinciding with loss of accessibility at Myc/E2f enhancers and gain of accessibility at FOXO targets.
• Prediction 2: Rapamycin treatment will shift this inflection point earlier in pseudotime, such that cells at earlier transcriptional states already exhibit low phospho‑S6 and open stress‑response chromatin.
• Prediction 3: Genetic disruption of p300 acetyltransferase activity (e.g., heterozygous p300 knockout) will phenocopy rapamycin’s effect on the bifurcation point, whereas FOXO1 deletion will abolish the shift to open stress‑response chromatin even under rapamycin.
• Prediction 4: Artificially maintaining high mTORC1 activity (via Rheb overexpression) in aged cells will prevent the chromatin closing at proliferation enhancers, keeping cells trapped in a proliferative state and increasing senescence markers due to replication stress.

Falsifiability

If scATAC‑seq data show no coordinated closing of proliferation enhancers concurrent with the mTOR activity drop, or if rapamycin does not alter the timing of chromatin changes along pseudotime, the hypothesis is falsified. Similarly, if FOXO deletion does not block rapamycin‑induced opening of stress‑response promoters, the proposed mutual‑inhibition mechanism is invalid.

Broader Implications

Demonstrating that mTOR functions as a tunable chromatin‑based switch reframes longevity interventions not as simple suppression of growth but as timed modulation of cell‑fate decisions. It suggests that the therapeutic window for rapamycin depends on where a cell resides along its differentiation‑stress continuum, offering a rationale for intermittent dosing schedules that preserve "civilization" functions while still engaging "survival" programs.